Nutra Pharma Corp.
Nutra Pharma is announcing the next phase of marketing their Over-the-Counter (OTC) pain reliever for dogs and cats, Pet Pain-Away™through their direct response partner, DEG Productions.
July 3, 2018 -- Coral Springs, Florida -- Nutra Pharma Corporation(OTC: NPHC), a biotechnology company marketing Nyloxin®and Pet Pain-Away™in the over-the-counter (OTC) pain management market, announced today that DEG Productions has signed an exclusive distribution deal with one of the nation’s leading direct mail marketers to launch a private label version of Pet Pain-Away™.
“Since we announced the new Pet Pain-Away marketing campaign by DEG, they have already created expanding product sales and a spike in national product recognition,” commented Rik J Deitsch, CEO of Nutra Pharma Corporation. "DEG is creating sales and educating new product users through infomercials (direct marketing) as well as online marketing and social media," he continued. "Their advertising features companion animals that are actual product users. This new agreement will allow access to a large population of the country that may not see the online or television advertising, but can be reached through catalog sales and direct mail marketing. It’s a completely untapped market for our products and includes millions of pet owners," he concluded.
Pet Pain-Away is a homeopathic, non-narcotic, non-addictive, over-the-counter pain reliever. The product is primarily aimed at treating moderate to severe chronic pain in companion animals. It is specifically indicated to treat pain from hip dysplasia, arthritis pain, joint pain, and general chronic pain in dogs and cats. Specialized proteins in Pet Pain-Away block the action of acetylcholine, a major stimulating neurotransmitter in the nervous system and activator of the inflammatory pathways. As a result, the pain and inflammation pathways are temporarily shut off.
“We are very excited about the sales opportunity that this highly targeted campaign presents,” commented Dan Sladkus, Co-President of DEG Productions. “The product will be marketed nationally to a proven list of pet product buyers through a stand-alone custom mailer,” he continued. “Due to the substantial nature of this list, which can reach millions of pet owners throughout the country, we feel that we will be able to educate new customers about the benefits of the product in a highly focused and efficient way,” he concluded.
The direct mail campaign is complimentary to the ongoing television campaign in that it is designed to acquire new customers and convert them into the monthly auto-ship program.
According to The American Pet Products Association (APPA) there are 89.7 million dogs and 94.2 million cats in the US. These companion animals are as susceptible as humans to ailments that require pain-relieving solutions. The total market for companion animals in the US reached an estimated $69.5 billion in 2017. Of these expenditures, over $15 billion was spent on medication for the animals. Additionally, a 2009 survey conducted by Virbac Pharmaceuticals puts the annual US market for companion animal pain relievers at more than $250 million.
For additional information on DEG Productions, visit: http://www.degproductions.tv
About Nutra Pharma Corp.
Nutra Pharma Corporation operates as a biotechnology company specializing in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases, including Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain. Additionally, the Company markets drug products for sale for the treatment of pain under the brand Nyloxin® and Pet Pain-Away™.
For additional information about Nutra Pharma, visit:
This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The private label direct mail campaign should not be construed as an indication in any way whatsoever of the future value of the Company’s common stock or its financial value. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.